Sugi Predict

Sugi Predict / Compounds / SCHEMBL532484

SCHEMBL532484

SCHEMBL532484

COc1ccc2c(c1)CCNC2

nearest known ligand 0.86

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CD274 Q9NZQ7 2/20 0.59
▸ HTR2C P28335 2/20 0.57
▸ HTR2A P28223 1/20 0.57
▸ HTR2B P41595 1/20 0.57
▸ KCNH2 Q12809 1/20 0.57
▸ RYR2 Q92736 1/20 0.57
▸ ASIC3 Q9UHC3 1/20 0.55
▸ DRD2 P14416 2/20 0.51
▸ DRD3 P35462 2/20 0.51
▸ HRH3 Q9Y5N1 1/20 0.50
▸ DRD1 P21728 1/20 0.50
▸ DRD5 P21918 1/20 0.50
▸ ADRA2A P08913 1/20 0.49
▸ ADRA2B P18089 1/20 0.49
▸ ADRA2C P18825 1/20 0.49
▸ HTR7 P34969 1/20 0.49
▸ NISCH Q9Y2I1 1/20 0.49
▸ LMNA P02545 1/20 0.49
▸ CYP1A2 P05177 1/20 0.49
▸ CYP2D6 P10635 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8467911 1.00 CD274 (0.59) CD274HTR2CHTR2AHTR2BKCNH2
Hydrochloric Acid SCHEMBL587493 0.98 CD274 (0.58) CD274HTR2CHTR2AHTR2BKCNH2
SCHEMBL29558442 0.93 HTR2C (0.57) CD274HTR2CHTR2AHTR2BKCNH2
SCHEMBL746109 0.93 HTR2C (0.57) CD274HTR2CHTR2AHTR2BKCNH2
Hydrochloric Acid SCHEMBL1124555 0.91 HTR2C (0.55) CD274HTR2CHTR2AHTR2BKCNH2
Hydrochloric Acid SCHEMBL31062521 0.91 HTR2C (0.55) CD274HTR2CHTR2AHTR2BKCNH2
Oxalic Acid SCHEMBL7199943 0.91 CD274 (0.52) CD274HTR2CHTR2AHTR2BKCNH2
SCHEMBL29758918 0.89 KCNH2 (0.54) CD274HTR2CHTR2AHTR2BKCNH2
SCHEMBL4859823 0.89 KCNH2 (0.54) CD274HTR2CHTR2AHTR2BKCNH2
Bromide SCHEMBL19644475 0.89 CD274 (0.51) CD274HTR2CHTR2AHTR2BKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 482 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12294088-B2 Secondary Li ion battery and Li capacitor electrode compositions HENKEL AG & CO. KGAA (DE) 2025-05-06 — — US claimed
EP-3555939-B1 IMPROVED SECONDARY LI ION BATTERY AND LI CAPACITOR ELECTRODE COMPOSITIONS HENKEL AG & CO KGAA (DE) 2025-02-05 — — EP claimed
US-11791468-B2 Secondary Li ion battery and Li capacitor electrode compositions HENKEL AG & CO. KGAA (DE) 2023-10-17 — — US claimed
US-20230307657-A1 SECONDARY Li ION BATTERY AND Li CAPACITOR ELECTRODE COMPOSITIONS HENKEL AG & CO. KGAA (DE) 2023-09-28 — — US claimed
CN-110050365-B Improved secondary lithium ion battery and lithium capacitor electrode compositions 汉高股份有限及两合公司 2023-04-28 — — CN claimed
CN-111621805-B Method for preparing 3, 4-dihydroisoquinoline by electrocatalytic selective dehydrogenation 天津大学 2022-02-18 — — CN claimed
CN-110294758-B 2-substituted 5, 6-dihydropyrazolo [5, 1-alpha ] isoquinoline, derivatives and synthesis method thereof 湘潭大学 2021-10-22 — — CN claimed
CN-109293569-B Method for preparing formamide derivative through amine transfer reaction without participation of catalyst 湘潭大学 2021-08-06 — — CN claimed
CN-109943861-B Method for synthesizing alpha-phosphoramidate by electrochemical oxidation 南京大学 2020-11-27 — — CN claimed
CN-111621805-A Method for preparing 3, 4-dihydroisoquinoline by electrocatalytic selective dehydrogenation 天津大学 2020-09-04 — — CN claimed
US-20040019083-A1 Asymmetric synthesis of (S,S,R)-(-)-actinonin and its analogs and uses therefor SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH 2004-01-29 — — US claimed
US-6562836-B1 Islet amyloid polypeptide (IAPP) is known to be capable of forming fibrils which are deposited in the pancreas of patients wtih type II diabetes QUEEN'S UNIVERSITY OF KINGSTON (CA) 2003-05-13 — — US claimed
US-20020198156-A1 Asymmetric synthesis of (S,S,R)-(-)-actinonin and its analogs and uses therefor SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH 2002-12-26 — — US claimed
EP-1025165-A4 PROCESS AND COMPOSITIONS CONTAINING POLYPHENOL COPOLYMERS HENKEL CORP (US) 2001-06-13 — — EP claimed
EP-1025165-A1 PROCESS AND COMPOSITIONS CONTAINING POLYPHENOL COPOLYMERS HENKEL CORPORATION (US) 2000-08-09 — — EP claimed
WO-1999016827-A1 PROCESS AND COMPOSITIONS CONTAINING POLYPHENOL COPOLYMERS HENKEL CORPORATION (US) 1999-04-08 — — WO claimed
US-5891952-A FREE OF ORGANIC SOLVENTS; REACTION PRODUCTS OF A PHENOLIC POLYMER SUCH AS POLYVINYLPHENOL, A BASE, AN AMINE, AN ALDEHYDE OF KETONE OR MIXTURE; USE AS SURFACE COATINGS HENKEL CORPORATION (US) 1999-04-06 — — US claimed
EP-0461113-A1 TANNIN MANNICH ADDUCTS FOR IMPROVING CORROSION RESISTANCE OF METALS HENKEL CORPORATION (US) 1991-12-18 — — EP claimed
US-4944812-A Tannin mannich adducts for improving corrosion resistance of metals HENKEL CORPORATION (US) 1990-07-31 — — US claimed
WO-1990005794-A1 TANNIN MANNICH ADDUCTS FOR IMPROVING CORROSION RESISTANCE OF METALS HENKEL CORPORATION (US) 1990-05-31 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020198156-A1 Asymmetric synthesis of (S,S,R)-(-)-actinonin and its analogs and uses therefor HASPIN, CYTH2, ACTR3 CD274 3951/4885HTR2C 168/4885HTR2A 1149/4885
US-20040019083-A1 Asymmetric synthesis of (S,S,R)-(-)-actinonin and its analogs and uses therefor HASPIN, CYTH2, CYTH3 CD274 3926/4885HTR2C 157/4885HTR2A 1114/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.